Calviri
Kathryn Sykes has decades of experience inventing and developing innovative molecular, genetic and biochemical technologies to manipulate the immune system towards better health. She grew the labs at HealthTell and served as V.P. of Research. Previously, she was a professor in the School of Life Sciences at the Biodesign Institute at Arizona State University. At the University of Texas Southwestern Medical School she pursued technologies that became the basis of a Texas biotechnology company, ultimately acquired by Macrogenics. Dr. Sykes received her B.S. in Biology and Economics from Duke University and her Ph.D. in Biochemistry and Genetics from Duke University Medical Center.
Calviri
Calviri’s mission is to provide affordable products worldwide that will end deaths from cancer. They are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. They focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer.